Pharma Journalist -

Novartis has announced positive topline results from its pivotal Phase III RemIND trial evaluating oral remibrutinib in patients with chronic inducible urticaria (CIndU), a condition…
Read More...

Johnson & Johnson has unveiled new data from its Phase 1b/2 OrigAMI-4 study, demonstrating that first-line treatment with investigational subcutaneous amivantamab and…
Read More...

Boehringer Ingelheim India Private Limited has signed a Memorandum of Understanding (MoU) with National Institute of Pharmaceutical Education and Research, Raebareli (NIPER Raebareli),…
Read More...

Catalent and S.Biomedics have entered into a strategic partnership to advance the development and manufacturing of TED-A9, an investigational allogeneic pluripotent stem cell-derived…
Read More...

Johnson & Johnson has announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, further…
Read More...

Unnatural Products, Inc. (UNP), a biotechnology company focused on developing orally delivered macrocyclic peptides for hard-to-drug targets, has entered into a research collaboration…
Read More...

Scribe Therapeutics, Inc. has achieved a second success milestone in its ongoing collaboration with Eli Lilly and Company, marking further progress in the development of in vivo…
Read More...

Teijin Pharma Limited has signed a joint research agreement with Aska Pharmaceutical Co., Ltd. to develop new small-molecule drug candidates for gynecological diseases, marking a…
Read More...

The Investigative & Preclinical Toxicology Summit (May 12-14 | Boston, MA) is set to redefine toxicology meetings for biotech and pharmaceutical professionals. Unlike traditional…
Read More...

Immunic, Inc. announced it has priced a private placement expected to generate up to $400 million in gross proceeds, funding the company’s shift from a research-focused biotech to a…
Read More...